Metabolic & Bariatric Surgery

Vol. 2, Issue 6 | August 18, 2026 | Closing the gaps in knowledge...

Editor note: This issue reflects the weekly Editorial Board ballot. Ballots were counted from Dr. Jerry Dang, MD PhD; Phil Schauer; Samer Mattar; Shanu Kothari, MD FACS; and Teresa LaMasters. No fallback sections were used.

A — Metabolic Surgery Research

Cremona, Cohen, Pattou, Casajoana, Sampaio Souza, Raverdy, Verkindt et al. | JAMA Network Open, 2026 | Source ↗

Cremona and colleagues apply the Lancet clinical and preclinical obesity framework to a global population of people being considered for metabolic and bariatric surgery. Rather than treating BMI as the full diagnosis, the analysis asks how many candidates would meet criteria for clinical obesity once organ dysfunction, symptoms, and obesity-related limitations are considered. The practical finding is that a disease-based definition can shift prevalence estimates and may sort surgical candidates differently than BMI thresholds alone. The study gives the field a way to discuss eligibility, severity, and prioritization using clinical burden instead of a single anthropometric cutoff.

For bariatric surgeons, this is more than a nomenclature exercise. Programs already know that two patients with the same BMI can carry very different operative risk, disability, and metabolic urgency. A clinical-obesity framework could improve referral triage, payer conversations, documentation, and shared decision-making if it is implemented carefully. It also creates work: teams will need consistent ways to capture functional impairment, metabolic disease, and organ complications without adding another opaque barrier to care.

Huynh, Prosser, Manasa, Peng, Mai, Pandey, Li, Butchy, Rogers, Carter | JAMA Surgery, 2026 | DOI source

Huynh and colleagues studied 383 adults undergoing primary bariatric surgery at UCSF and compared patients with and without preoperative GLP-1 receptor agonist exposure. The retrospective cohort found no meaningful association between preoperative GLP-1 use and 12-month total weight loss after surgery. The same pattern held across practical perioperative outcomes, including diabetes control, operative time, hospital length of stay, emergency department use, and complications. The message is narrow but useful: in this cohort, GLP-1 exposure before surgery neither improved nor harmed early surgical outcomes.

That nuance matters in clinic. Patients increasingly arrive having tried semaglutide, tirzepatide, or another GLP-1 agent before referral, and surgeons need to avoid both punitive and promotional framing. Prior medication use should not be treated as evidence that surgery will fail, nor should it be oversold as a way to make surgery work better. The data support a more practical conversation about sequencing, medication tolerance, insurance interruptions, nutrition, glycemic optimization, and the reason the patient is now pursuing an operation.

Corpodean, Kachmar, Popiv, Saquer, Lovelace, Lenhart, Cook, Aminian, Cohen, Albaugh, Schauer | Obesity Reviews, 2026 | DOI source

Corpodean and colleagues provide a 10-year bibliometric update of the 100 most cited papers in metabolic and bariatric surgery. The paper is not an outcomes study in the usual sense; it is a map of the literature that has most strongly influenced the field. The analysis tracks citation patterns, leading themes, authorship, journals, and the way scientific priorities have shifted as bariatric surgery became metabolic surgery. It also helps identify which landmark papers continue to anchor current guidelines, teaching, and clinical debates.

For surgeons, the value is educational and strategic. Citation counts do not prove clinical truth, but they show which evidence has shaped practice, reimbursement, research funding, and trainee understanding. Programs can use this kind of map to update journal clubs, fellowship curricula, and onboarding for new team members. It also reminds us that some high-impact questions, especially long-term access, durability, disparities, revision, and combination therapy, need the same level of sustained scholarship as the classic weight-loss and diabetes-remission trials.

Kachmar, Corpodean, Garcia Navas, Perkins, Galvani, Cook, Danos, Hughes, Schauer, Albaugh | Obesity, 2026 | DOI source

Kachmar and colleagues analyzed more than 11.6 million ACS NSQIP surgical cases from 2005 through 2022 to test whether patients in higher BMI categories were receiving a growing share of operative care as severe obesity became more common. The opposite pattern emerged. After adjustment, patients with BMI 50 kg/m2 or higher accounted for a declining proportion of surgical operations over time, with larger declines at higher BMI levels. Patients with BMI 30 to 39.9 kg/m2 showed increasing proportional operative volume.

This is an access-to-care paper disguised as a surgical epidemiology paper. Bariatric surgeons see the downstream consequences when operating rooms, imaging equipment, anesthesia pathways, transfer policies, and referral networks are not designed for patients with the highest BMI. The findings should push hospitals to ask whether severe obesity is being managed as a routine part of surgical care or quietly filtered out through infrastructure limits. For MBS programs, the study strengthens the argument that obesity treatment is also surgical access work across the hospital.

B — Science of Obesity Metabolism

Tran, Zhang, Hartmann | Obesity Science & Practice, 2026 | PMC full text

Tran, Zhang, and Hartmann used NHANES data from 2000 through 2023 to characterize adults with BMI 50 to 59.9 kg/m2 and BMI 60 kg/m2 or higher. The analysis included 54,793 adults for prevalence and comorbidity analyses, with mortality data available for 43,454 participants. The prevalence of obesity classes 4 and 5 rose from 0.6% in 2000 to 2.2% in 2023, a more than 250% increase. These groups also carried markedly higher odds of metabolic comorbidities and higher 10-year mortality than adults without obesity and those in classes 1 to 3.

The study puts numbers behind what high-volume programs already feel. The most severe end of the obesity spectrum is growing, and these patients are not simply larger versions of lower-risk patients. They often need more imaging capacity, more careful anesthesia planning, stronger mobility support, different operating-room logistics, and earlier treatment before comorbidity burden compounds. Bariatric surgeons should use data like this to advocate for systems built around actual patient need rather than historical BMI distributions.

Hubert, Coleman, Grosicki, Kiel, Shepherd, Lofton, Heymsfield, Thomas, Dhurandhar, Jonnalagadda | Journal of the Academy of Nutrition and Dietetics, 2026 | DOI source

Hubert and colleagues used Hall’s human metabolism model to examine long-term weight trajectories during GLP-1 receptor agonist treatment, anchored to trial-derived baseline characteristics. The model projected large early weight loss, followed by a prolonged plateau despite continued medication. In the modeled trajectory, energy intake fell sharply at first, then gradually rose until it approached energy expenditure, while energy expenditure also declined with weight loss. After discontinuation, intake exceeded baseline and some weight loss was reversed.

This is a helpful counseling tool because a plateau often gets interpreted as medication failure. The model suggests a different explanation: the biology has reached a new energy-balance point. Surgeons and obesity-medicine clinicians can use that frame when discussing nutrition adequacy, resistance training, behavioral support, dose continuity, and when to consider surgery or combination therapy. The paper is open access under a CC BY-NC-ND license, so this entry summarizes the work rather than reproducing text or tables.

Marilynn Larkin | Medscape Medical News, 2026 | Source ↗

Medscape Medical News surveys a wide 2026 obesity-drug pipeline that extends well beyond current weekly GLP-1 therapy. The overview includes oral combinations, monthly or quarterly incretin strategies, nutrient-sensing approaches, live biotherapeutics, amylin pathways, triple agonists, and body-composition concepts. Because no single underlying primary document was identified for the entire story, this Digest entry treats the article as a secondary pipeline overview rather than as independent clinical evidence. The useful point is the breadth of mechanisms and dosing strategies now being pursued.

For bariatric surgeons, the pipeline should change counseling without turning every consult into drug-company forecasting. Patients will keep asking about pills, less frequent injections, retatrutide, amylin combinations, and therapies that promise lean-mass preservation. Surgeons do not need to predict winners, but they do need a framework: mechanism, phase of development, magnitude of weight loss, adverse effects, durability, access, and how the drug might sequence with surgery. The more crowded the pipeline gets, the more valuable clear surgical counseling becomes.

Will Pass | Medscape Medical News / ASCO abstracts, 2026 | Source ↗

Medscape reports two observational ASCO analyses evaluating GLP-1 receptor agonist exposure and breast cancer incidence in women with overweight or obesity. One analysis, presented at the 2026 ASCO Annual Meeting, studied more than 111,000 screened women and found lower odds of breast cancer among GLP-1 users after matching. A second analysis focused on more than 80,000 high-risk women with obesity and found a smaller but still significant association. The studies are retrospective and observational, so they should be read as hypothesis-generating.

The bariatric relevance is the cancer-prevention conversation, not a new indication for GLP-1 prescribing. Weight loss after MBS has long been associated with lower risk for several obesity-related cancers, and incretin therapy is now entering the same research space. Surgeons should avoid causal language and should not suggest GLP-1 therapy for breast cancer prevention based on these abstracts. The practical implication is that obesity treatment, whether surgical, medical, or combined, is increasingly being studied through oncology as well as cardiometabolic endpoints.

C — Metabolic Innovation and Technology

Nagda, Lee, Thompson, Park, Strother, Liévin, Ruparel, Goel, Bergamaschi, Bedi et al. | Google Research / Google DeepMind / arXiv, 2026 | arXiv source

Nagda and colleagues describe AMIE Video, a Gemini-based multi-agent system designed for real-time medical video consultations. The arXiv preprint reports performance in structured consultation scenarios, including OSCE-style evaluation against physician comparators. The system reportedly matched or exceeded primary-care physicians on several rubric-based measures, while still showing weaknesses in rapport, subtle affect, and fine physical-exam perception. Because this is a preprint and not bariatric-specific, it should be treated as an innovation signal rather than clinical implementation evidence.

For bariatric programs, the near-term question is not whether AI should replace visits. It is whether narrow, governed tools can improve preoperative education, longitudinal follow-up, triage, and access between in-person encounters. Video-based AI raises additional concerns around consent, privacy, equity, liability, physical-exam limits, and escalation when a patient is clinically unsafe. Surgeons should watch the technology, but adoption should wait for specialty-specific validation and clear human supervision.

Jim Hammerand | Medical Design & Outsourcing, 2026 | Source ↗

Medical Design & Outsourcing reports Levita Magnetics CEO Alberto Rodriguez-Navarro’s view that GLP-1 drugs may increase demand for bariatric surgery over time. His argument is that medication cost, adherence, side effects, and durability concerns may lead some patients to seek a more durable procedural option. The article also places Levita’s MARS magnetic-assisted robotic surgery platform in the context of bariatric and high-volume abdominal operations. This is a trade-publication interview, so it should be read as device-sector perspective rather than outcomes evidence.

Surgeons should separate two issues that often get blended together: whether GLP-1 therapy changes bariatric volume, and whether a specific robotic platform improves bariatric surgery. The first is a referral and sequencing question. The second requires procedure-specific data on exposure, stapling, hiatal work, operative time, complications, ergonomics, cost, and training. The article is still useful because it shows how device companies are planning around obesity pharmacotherapy rather than assuming surgery disappears.

American Society for Metabolic and Bariatric Surgery | ASMBS, 2026 | Program page

ASMBS has opened applications for the 2026-2027 Surgical Technique and Advanced Robotics Training program. The non-CME program is designed for fellows in Fellowship Council-approved bariatric fellowships and combines virtual didactics, local mentorship, and hands-on training at a robotics facility. Eligibility requirements include ASMBS membership or application, senior fellow status, institutional access to a da Vinci X or Xi system, mentor commitment, and defined robotic case-volume expectations. Applications run from August 15 through September 30, 2026.

This matters because robotics training is becoming part of bariatric workforce development rather than a late-career add-on. A structured fellowship pathway can help standardize exposure to robotic sleeve, bypass, revisional, hiatal, and complication-management principles. The case-volume requirements also put responsibility on programs, not just trainees, to provide meaningful operative access and mentorship. For directors, the announcement is a prompt to identify eligible fellows early and decide whether the institution can support the required pathway.

D — Metabolic Marketplace

Dave Muoio | Fierce Healthcare, 2026 | Source ↗

Fierce Healthcare reports that PatientRightsAdvocate.org sued the American Medical Association seeking free public access to Current Procedural Terminology codes. The lawsuit argues that CPT has become embedded in government systems and electronic health-care transactions, making public use effectively unavoidable. Fierce also reports the group’s challenge to AMA licensing fees and its intent to post CPT publicly if the court agrees. The underlying complaint was not retrieved during production, so this entry relies on Fierce’s coverage of the filing and related policy context.

This is not bariatric-specific, but it sits close to bariatric practice economics. Procedure coding affects payment, prior authorization, billing transparency, documentation, data reporting, and the ability of patients to understand what care costs. Any disruption to CPT governance would ripple through surgical specialties, including MBS, even if the litigation takes years. Surgeons should follow the policy fight while keeping the clinical focus on accurate coding, fair reimbursement, and transparent communication with patients.

Meghana Keshavan / The Readout | STAT News, 2026 | Source ↗

STAT reports that Eli Lilly is targeting illicit sales of investigational retatrutide, a next-generation incretin drug still outside routine clinical availability. The accessible portion of the STAT+ article identifies black-market demand for “reta” and places the story in a broader biotech-market newsletter. Because the full article is paywalled, this Digest entry treats the item as marketplace reporting rather than clinical evidence. The important signal is that consumer demand is already moving ahead of approval, labeling, manufacturing controls, and physician supervision.

Bariatric and obesity-medicine practices should assume some patients are hearing about retatrutide through online channels before they hear about it from clinicians. That creates safety questions around counterfeit products, dosing errors, compounding claims, side effects, and unrealistic expectations from phase 3 headlines. Surgeons do not need to police the internet, but they should ask directly and nonjudgmentally about medication sourcing. Patients are more likely to disclose risky behavior when the question is routine rather than accusatory.

Production Editor: John D. Scott, MD, FACS | [email protected]

We welcome inquiries, tips, letters to the editor, and article ideas from the MBS community. Reach us at [email protected].

The MBS Digest | August 18, 2026 | Vol. 2, Issue 6 | For Educational Purposes Only | Not for Redistribution